Ipca Laboratories Financial Statements

Ipca Laboratories (IPCALAB) reported revenue of ₹90.32B in FY2025 with net income of ₹7.85B. Total assets stood at ₹117.61B and free cash flow was ₹5.46B.

Ipca Laboratories Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		54.20B	58.96B	63.70B	78.30B	90.32B
Cost of Rev. Cost of Revenue		-17.28B	-20.15B	-23.07B	-25.76B	-27.79B
Gross Profit		36.92B	38.82B	40.63B	52.54B	62.54B
SGA Sales, General & Admin		-21.47B	-25.06B	-30.11B	-38.08B	-44.35B
Op. Income Operating Income		13.35B	11.43B	7.91B	10.89B	14.21B
PBT Profit Before Tax		13.89B	11.36B	7.45B	8.43B	11.31B
Net Income		11.40B	8.90B	4.79B	5.23B	7.85B
Dil. Shares Diluted Shares		252.88M	253.70M	253.70M	253.70M	253.67M
Diluted EPS		45.08	34.85	18.58	21.57	29.08

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Ipca Laboratories's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Ipca Laboratories Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		34.37B	44.57B	51.89B	55.39B	62.69B
Non-curr. assets Total non-current assets		26.31B	31.66B	34.37B	55.62B	54.92B
Total assets		60.68B	76.24B	86.26B	111.01B	117.61B
Curr. liabilities Total current liabilities		11.33B	14.66B	18.06B	23.56B	23.86B
Non-curr. liab. Total non-current liabilities		2.19B	6.16B	9.05B	10.19B	9.86B
Total liabilities		13.52B	20.82B	27.11B	33.74B	33.72B
Total equity		47.16B	55.42B	59.15B	77.27B	83.88B
Total liab. & eq. Total liabilities & equity		60.68B	76.24B	86.26B	111.01B	117.61B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Ipca Laboratories's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Ipca Laboratories Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		13.81B	11.36B	7.45B	8.43B	11.31B
Operating CF Cash flow Operating Activities		10.90B	8.56B	8.06B	9.45B	13.21B
Capex Investments in PPE		-3.62B	-4.79B	-4.94B	-4.11B	-7.76B
Investing CF Cash flow Investing Activities		-5.21B	-8.55B	-7.25B	-12.92B	-8.70B
Dividend Paid		-1.02B	-1.01B	-1.01B	-507.40M	-1.01B
Financing CF Cash flow Financing Activities		-3.06B	4.27B	5.07B	-5.53B	-2.83B
Cash (start) Cash at beginning of period		2.95B	5.59B	9.91B	15.79B	7.56B
Cash (end) Cash at end of period		5.59B	9.91B	15.79B	7.56B	9.25B
FCF Free Cash Flow		7.29B	3.77B	3.11B	5.34B	5.46B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Ipca Laboratories's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025